Halozyme Therapeutics (HALO) develops enzyme-based (hyaluronidase) products for a wide variety of conditions, which include diabetes, cancer, autoimmune disorders and cosmetic medicine (cellulite).
CLINICAL AND REGULATORY CATALYSTS:
Below is a summary of the company's clinical development pipeline which includes collaborations with Roche (OTC:RHHBY), Pfizer (PFE), Baxter (BAX) and ViroPharma (VPHM) in addition to an FDA approved product, HYLENEX (human recombinant formulation of hyaluronidase), which improves the absorption and dispersion of drugs injected under the skin (subcutaneously) (e.g. insulin) on a temporary basis (approximately 24 hours) with plans to increase sales through a recently initiated post-marketing study in Type 1 diabetes using insulin pumps.
1.) Herceptin-SC (trastuzumab) and MabThera-SC (rituximab)...
Only subscribers can access this article, which is part of the PRO research library covering 3,553 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: